Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 10/20 | 1.00 |
| ▸ | MAPK14 | Q16539 | 9/20 | 1.00 |
| ▸ | KIT | P10721 | 8/20 | 1.00 |
| ▸ | KDR | P35968 | 8/20 | 1.00 |
| ▸ | SRC | P12931 | 3/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 0.84 |
| ▸ | CSF1R | P07333 | 3/20 | 0.82 |
| ▸ | BRAF | P15056 | 3/20 | 0.71 |
| ▸ | BTK | Q06187 | 5/20 | 0.67 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.61 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.61 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2947918 | 0.91 | LCK (1.00) | LCKMAPK14KITKDRSRC | |
| SCHEMBL2949011 | 0.89 | LCK (0.80) | LCKMAPK14KITKDRSRC | |
| SCHEMBL2944391 | 0.88 | KIT (0.78) | LCKMAPK14KITKDRSRC | |
| SCHEMBL2951430 | 0.87 | LCK (1.00) | LCKMAPK14KITKDRSRC | |
| SCHEMBL2952329 | 0.87 | MAPK14 (0.77) | LCKMAPK14KITKDRSRC | |
| SCHEMBL2950966 | 0.85 | KDR (1.00) | LCKMAPK14KITKDRSRC | |
| SCHEMBL2943439 | 0.85 | MAPK14 (0.79) | LCKMAPK14KITKDRSRC | |
| SCHEMBL2949699 | 0.85 | MAPK14 (0.78) | LCKMAPK14KITKDRSRC | |
| SCHEMBL25951683 | 0.84 | MAPK14 (0.73) | LCKMAPK14KITKDRSRC | |
| SCHEMBL15987528 | 0.84 | KIT (0.72) | LCKMAPK14KITKDRSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492404-B2 | Bis-aryl amide compounds and methods of use | AMGEN INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-20100234373-A1 | BIS-ARYL AMIDE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-7754717-B2 | Bis-aryl amide compounds and methods of use | AMGEN INC. (US) | 2010-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234373-A1 | BIS-ARYL AMIDE COMPOUNDS AND METHODS OF USE | LCK, BTK, IRAK1 | LCK 1/4885MAPK14 525/4885KIT 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.